These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23393185)

  • 1. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
    Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
    Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
    Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.
    Kadowaki T; Jinnouchi H; Kaku K; Hersløv ML; Hyllested-Winge J; Nakamura S
    J Diabetes Investig; 2016 Sep; 7(5):711-7. PubMed ID: 27182031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25507175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
    Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
    Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 13. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
    Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
    Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
    Davies MJ; Gross JL; Ono Y; Sasaki T; Bantwal G; Gall MA; Niemeyer M; Seino H;
    Diabetes Obes Metab; 2014 Oct; 16(10):922-30. PubMed ID: 24702700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
    Kumar S; Jang HC; Demirağ NG; Skjøth TV; Endahl L; Bode B
    Diabet Med; 2017 Feb; 34(2):180-188. PubMed ID: 27027878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes.
    Urakami T; Kuwabara R; Aoki M; Okuno M; Suzuki J
    Endocr J; 2016; 63(2):159-67. PubMed ID: 26632171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
    Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
    Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes].
    Lüdemann J; Milek K; Wilhelm B; Segner A; Jaeckel E
    MMW Fortschr Med; 2014 Oct; 156 Suppl 3():89-97. PubMed ID: 25417447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.